Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

By sjmartinez • August 22, 2024

Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, Wang S, Yin J, Ding L, Ran X, Fan S, Sun Q, Tan SY, Koeffler HP, Li J, Mi Y, Chen YQ. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024 Aug 19:134844. doi: 10.1016/j.ijbiomac.2024.134844. Epub ahead of print. PMID: 39168191.

Tags: castration-resistant prostate cancer, Drug-tolerant persister, Hematology/Oncology, Nuclear factor erythroid 2-related factor 2, peroxiredoxin 5, Publications, stachyose, Stachyose caproate

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi:[...]